Financial Results and Clinical Study Outcomes - Research Report on Agilent, Perrigo, Lilly, Novavax, and Raptor Pharmaceutical

 Financial Results and Clinical Study Outcomes - Research Report on Agilent,
              Perrigo, Lilly, Novavax, and Raptor Pharmaceutical

PR Newswire

NEW YORK, August 20, 2013

NEW YORK, August 20, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Agilent
Technologies Inc. (NYSE: A), Perrigo Company (NYSE: PRGO), Eli Lilly & Co.
(NYSE: LLY), Novavax, Inc. (NASDAQ: NVAX), and Raptor Pharmaceutical Corp.
(NASDAQ: RPTP). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Agilent Technologies Inc. Research Report

On August 14, 2013, Agilent Technologies Inc. (Agilent) reported its Q3 FY
2013 financial results (period ended July 31, 2013) with net revenue down 4.1%
YoY to $1.7 billion. Net income was $168 million or $0.49 per diluted share
compared to $243 million or $0.69 per diluted share in Q3 FY 2012. Non-GAAP
net income stood $0.68 per diluted share compared to $0.79 in Q3 FY 2012.
Agilent CEO Bill Sullivan said, "Although we are operating in a very
challenging economic environment, we are pleased with our operational
performance, as we continue to make progress improving our manufacturing
efficiency and streamlining our expense structure. The result has been better
than forecasted operating margins." Agilent anticipates Q4 FY 2013 revenues to
be within $1.7 billion to $1.72 billion and non-GAAP earnings between $0.75
and $0.77 per share. For FY 2013, the Company expects revenues of $6.76
billion to $6.78 billion and non-GAAP earnings of $2.83 to $2.85 per share.
The Full Research Report on Agilent Technologies Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-08-16/A]

--

Perrigo Company Research Report

On August 15, 2013, Perrigo Company (Perrigo) reported its Q4 FY 2013 and
full-year FY 2013 financial results (period ended June 29, 2013). The
Company's net sales increased 16.3% YoY to $967.2 million during Q4 FY 2013
and increased 11.6% YoY to $3.5 billion for FY 2013. In Q4 FY 2013, income
from continuing operations was $118.5 million or $1.25 per diluted share,
compared to $107.1 million or $1.14 per diluted share in Q4 FY 2012. For FY
2013, net income stood at $441.9 million or $4.68 per diluted share, compared
to $401.6 million or $4.27 per diluted share in FY 2012. Perrigo's Chairman
and CEO Joseph C. Papa said, "This was a strong quarter where we continued to
successfully drive growth across our segments, while managing costs to
generate record bottom-line performance. With this backdrop, on July 29th, we
announced a definitive agreement to acquire Elan Corporation, which will
combine two great companies to create value for our respective shareholders,
patients and customers." Full Research Report on Perrigo Company - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-08-16/PRGO]

--

Eli Lilly & Co. Research Report

On August 15, 2013, Eli Lilly & Co. (Lilly) announced that data published in
The Lancet revealed that elderly people with type 2 diabetes (T2D) who were
treated for 24 weeks with dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin
(TRADJENTA) marketed by the Company and Boehringer Ingelheim Pharmaceuticals,
Inc., reported marked decline in blood glucose levels (HbA1c) compared with
those receiving placebo. In addition, the Company stated that the published
data showed that the overall safety and tolerability profile of linagliptin
was similar to placebo. Professor Anthony H. Barnett, MD, FRCP, Heart of
England NHS Foundation Trust and University of Birmingham, United Kingdom,
said, "Elderly individuals represent approximately 15 percent of people with
type 2 diabetes worldwide. This study may help inform treatment decisions for
improving glycemic control in the elderly."According to the Company, the study
of 2 years duration was conducted on 241 elderly people (with age >=70 years)
across five countries. The Full Research Report on Eli Lilly & Co. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-08-16/LLY]

--

Novavax, Inc. Research Report

On August 8, 2013, Novavax, Inc. (Novavax) reported its Q2 2013 financial
results with revenue down 50.3% YoY to $3.5 million. Net loss was $12.6
million or $0.08 per diluted share in Q2 2013, compared to net loss of $5.9
million or $0.05 per diluted share in Q2 2012.Stanley C. Erck, President and
CEO of Novavax, said, "In addition to the progress on our core product
candidates, last quarter highlighted Novavax's capabilities in responding to
emerging diseases. We took the initiative to rapidly develop and validate
vaccine candidates for both H7N9 and MERS, demonstrating our ability to serve
the needs of the global healthcare community through timely delivery of viable
vaccine candidates for such emerging threats."The Full Research Report on
Novavax, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-16/NVAX]

--

Raptor Pharmaceutical Corp. Research Report

On August 8, 2013, Raptor Pharmaceutical Corp. (Raptor Pharmaceutical)
reported its Q2 2013 financial results with net product sales (from PROCYSBI)
of $21,000 compared to no sales in Q2 2012. Net loss was $24.1 million or
$0.43 per diluted share, compared to net loss of $3 million or $0.06 per
diluted share in Q2 2012. Julie Anne Smith, Executive Vice President Strategy
and Chief Operating Officer, said, "We are seeing strong PROCYSBI demand from
both RaptorCares pre-registered patients, and new patients not previously
identified. We are therefore accelerating our timeline on the next stage of
our launch to identify misdiagnosed, undiagnosed or late-onset cystinosis
patients and potentially expand the addressable patient population." The Full
Research Report on Raptor Pharmaceutical Corp. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-08-16/RPTP]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.